Clinigen Appoints Greg Skalicky as Group CEO to Lead Next Phase of Global Growth and Patient Access Strategy
Clinigen, a global pharmaceutical services company dedicated to improving patient access to critical medicines around the world, has announced the appointment of Greg Skalicky as its new Group Chief Executive Officer, effective 20 July 2026. Skalicky succeeds Dr. Varun Sethi, who has served as Acting CEO since September 2025 and guided the company through a period of strategic development and operational progress.
The leadership transition marks an important milestone for Clinigen as it continues to strengthen its position as a trusted partner for pharmaceutical and biotechnology companies across the drug development and commercialization continuum. With more than three decades of experience in the pharmaceutical, biotechnology, and healthcare industries, Skalicky brings a combination of clinical knowledge, commercial expertise, and global leadership that is expected to support the company’s long-term growth strategy and expand its ability to help patients gain access to life-changing medicines.
Clinigen’s Board believes the appointment reinforces the company’s commitment to delivering integrated pharmaceutical services while responding to the evolving needs of the global life sciences industry.
A Leadership Transition Focused on Future Growth
The appointment of Greg Skalicky comes at a time when pharmaceutical companies are increasingly seeking partners capable of supporting multiple stages of the product lifecycle—from clinical development through commercialization and patient access.
Clinigen has steadily expanded its portfolio of specialized pharmaceutical services, helping biopharmaceutical companies navigate complex regulatory environments, manage global medicine supply, conduct clinical trial support programs, and provide access to investigational and approved medicines for patients with unmet medical needs.
As the company enters its next phase of development, its leadership believes that Skalicky’s broad industry experience will help accelerate strategic growth while strengthening customer partnerships across global markets.
His appointment follows the contributions of Dr. Varun Sethi, who has led the organization as Acting CEO since September 2025. During his tenure, Sethi helped maintain operational stability, advance strategic priorities, and position the company for continued expansion.
Bringing More Than Three Decades of Industry Experience
Greg Skalicky joins Clinigen with more than 30 years of leadership experience spanning the pharmaceutical, biotechnology, healthcare services, and commercialization sectors.
Throughout his career, he has led large international organizations, managed complex client relationships, and developed innovative business models designed to improve the delivery of healthcare products and services.
His professional background combines scientific understanding with commercial strategy, providing experience across both clinical and business operations.
This combination is particularly valuable for organizations such as Clinigen, which operate at the intersection of pharmaceutical development, regulatory requirements, patient access, and commercial execution.
Over the years, Skalicky has built a reputation for leading organizational transformation, supporting international expansion, and establishing strategic partnerships that enable pharmaceutical companies to bring medicines to patients more efficiently.
Leadership at Eversana
Before joining Clinigen, Skalicky most recently served as President of Eversana, a global provider of commercialization services for the life sciences industry.
During his tenure, he played a key role in designing and implementing what the company described as the industry’s first fully integrated commercialization model.
This approach combined multiple pharmaceutical support services—including market access, commercialization, patient services, medical affairs, and technology solutions—into a unified platform intended to simplify the commercialization process for pharmaceutical companies.
The experience provided Skalicky with extensive knowledge of the evolving needs of drug developers as they navigate increasingly complex global healthcare markets.
His work at Eversana also demonstrated an ability to integrate diverse service offerings into comprehensive solutions that improve operational efficiency and patient access.
Extensive Experience Across Pharmaceutical Services
Prior to Eversana, Skalicky held senior leadership positions at Syneos Health, formerly known as inVentiv Health, one of the world’s leading providers of outsourced biopharmaceutical services.
In these roles, he managed relationships with many of the industry’s largest pharmaceutical companies while overseeing global operations supporting clinical development and commercialization activities.
Earlier in his career, he also served in leadership roles at PharmaNet, another organization recognized for providing clinical research and pharmaceutical development services.
These experiences exposed him to virtually every stage of the pharmaceutical product lifecycle, including:
- Clinical research
- Drug development
- Regulatory support
- Commercial strategy
- Market access
- Patient engagement
- Global pharmaceutical partnerships
This broad perspective aligns closely with Clinigen’s integrated service model.
Leading Clinigen’s Next Chapter
As Group CEO, Skalicky will oversee Clinigen’s worldwide operations while guiding the company’s long-term strategic direction.
His responsibilities will include supporting continued growth across the organization’s core business segments, including:
- Clinical trial services
- Strategic staffing solutions
- Global compassionate use programs
- Pharmaceutical access services
- Supply chain support
- Commercial partnerships
The company intends to continue expanding its ability to support pharmaceutical and biotechnology organizations throughout every stage of the medicine development process.
Clinigen believes that increasing demand for specialized pharmaceutical services creates significant opportunities for long-term growth, particularly as more therapies are developed for rare diseases, oncology, advanced biologics, and personalized medicine.
Chairman Highlights Strategic Fit
Commenting on the appointment, Paul Carter, Chairman of Clinigen, described Greg Skalicky as an accomplished healthcare executive with extensive industry expertise and a demonstrated ability to scale global organizations successfully.
According to Carter, Skalicky’s experience spans commercialization, patient access, and pharmaceutical services, making him well positioned to guide Clinigen through its next stage of development.
He explained that the company’s long-term ambition is to provide pharmaceutical and biotechnology clients with a fully integrated partner capable of delivering comprehensive access solutions throughout the pharmaceutical lifecycle.
Carter noted that Skalicky’s leadership background closely aligns with this strategic vision and positions him to help expand the company’s global capabilities.
The Chairman also expressed appreciation for Dr. Varun Sethi’s contributions as Acting CEO, recognizing his leadership in strengthening the business and advancing important strategic initiatives during the transition period.
New CEO Emphasizes Patient-Centered Mission
Following the announcement of his appointment, Greg Skalicky expressed enthusiasm about joining Clinigen during what he described as an exciting stage in the company’s evolution.
He noted that Clinigen has earned a strong international reputation for helping solve some of healthcare’s most complex medicine access and supply challenges.
According to Skalicky, the company’s mission of improving patient access to critical therapies strongly aligns with his own professional values.
He emphasized that he looks forward to working closely with Clinigen’s global workforce to:
- Accelerate company growth
- Deliver greater value to pharmaceutical clients
- Expand patient access to critical medicines
- Strengthen customer relationships
- Continue advancing operational excellence
His comments underscore the company’s continued focus on balancing commercial growth with its broader healthcare mission.
Supporting Patients Around the World
Clinigen plays an important role within the global pharmaceutical ecosystem by helping ensure that patients gain timely access to medicines that may otherwise be difficult to obtain.
The company works with pharmaceutical manufacturers throughout multiple stages of product development and commercialization.
Among its services are programs that support:
- Clinical trial supply
- Early access to investigational medicines
- Compassionate use programs
- Managed access initiatives
- Regulatory support
- Global medicine distribution
- Strategic workforce solutions
These services become particularly valuable for therapies targeting rare diseases, oncology, and other serious medical conditions where treatment availability may vary significantly between countries.
By helping pharmaceutical companies navigate regulatory, logistical, and operational challenges, Clinigen contributes to improving global access to innovative therapies.
A Truly Global Organization
Today, Clinigen partners with more than 1,000 pharmaceutical and biotechnology companies around the world.
Its operations extend across five continents, providing services to organizations ranging from emerging biotechnology companies to many of the world’s largest multinational pharmaceutical manufacturers.
This broad international footprint enables the company to support medicine access across diverse healthcare systems while responding to regional regulatory requirements and market conditions.
As pharmaceutical innovation continues to expand globally, demand for organizations capable of coordinating international access programs is expected to grow.
Strategic Priorities Moving Forward
Under Skalicky’s leadership, Clinigen intends to maintain several strategic priorities that have guided the company’s recent growth.
These include:
- Operational excellence
- Strong customer partnerships
- Continued innovation
- Strategic international expansion
- Enhanced integrated service offerings
- Long-term sustainable growth
The company also plans to continue investing in capabilities that strengthen collaboration with pharmaceutical and biotechnology customers while improving access to medicines for patients worldwide.
The appointment of Greg Skalicky as Group Chief Executive Officer represents an important step in Clinigen’s ongoing evolution as a global pharmaceutical services provider. Bringing more than 30 years of leadership experience across healthcare, biotechnology, and pharmaceutical commercialization, Skalicky is expected to help guide the company through its next phase of strategic growth while reinforcing its commitment to improving patient access to critical medicines.
Building on a strong foundation established under Acting CEO Dr. Varun Sethi, Clinigen aims to further expand its integrated service model, deepen relationships with pharmaceutical and biotechnology partners, and continue supporting innovative therapies throughout the product lifecycle. With operations spanning five continents and partnerships with more than 1,000 life sciences organizations, the company remains focused on delivering operational excellence, fostering innovation, and ensuring that patients around the world gain faster access to the medicines they need.
About Clinigen
Clinigen is a global pharmaceutical services company trusted by pharmaceutical and biotechnology organisations worldwide. With decades of experience, Clinigen helps accelerate access to critical medicines across the product lifecycle. Headquartered in the UK with operations across Europe, the Americas, and Asia-Pacific, Clinigen’s purpose is to be the global pathfinder accelerating patient access to critical medicines. Clinigen was acquired by Triton Partners in April 2022.